Pegloticase Dosing for Refractory Gout
The recommended dose of pegloticase is 8 mg administered as an intravenous infusion every 2 weeks. 1
Standard Administration Protocol
- Infusion duration: Administer over no less than 120 minutes via gravity feed, syringe-type pump, or infusion pump 1
- Route: Intravenous infusion only—never administer as an IV push or bolus 1
- Frequency: Every 2 weeks (biweekly dosing) 1
Recent Evidence on Shorter Infusion Times
- A 60-minute infusion duration has been shown to be safe and effective when co-administered with methotrexate, with comparable safety and efficacy to the traditional 120-minute infusion 2
- However, the FDA-approved standard remains 120 minutes for pegloticase monotherapy 1
Critical Pre-Treatment Requirements
Before initiating pegloticase:
- Discontinue all oral urate-lowering agents (allopurinol, febuxostat) before starting pegloticase 1
- Screen for G6PD deficiency in patients at higher risk (African and Mediterranean ancestry) due to hemolysis and methemoglobinemia risk 1
- Pre-medicate with antihistamines and corticosteroids before each infusion to reduce anaphylaxis and infusion reaction risk 1
Monitoring and Treatment Duration
- Monitor serum uric acid levels before each infusion 1
- Consider discontinuing treatment if serum uric acid rises above 6 mg/dL, particularly when 2 consecutive levels above 6 mg/dL are observed, as this indicates loss of therapeutic response and increased infusion reaction risk 1, 3
- Treatment duration varies by patient response, with studies showing sustained benefit for up to 52 weeks in responders 4, 5
Gout Flare Prophylaxis
- Initiate gout flare prophylaxis (NSAID or colchicine) at treatment start and continue for at least 6 months unless medically contraindicated or not tolerated 1
- Gout flares frequently occur upon initiation but do not require pegloticase discontinuation 1
Administration Setting Requirements
- Must be administered in a healthcare setting by providers prepared to manage anaphylaxis and infusion reactions 1
- Monitor patients closely for an appropriate period after infusion for signs of anaphylaxis, which typically manifests within 2 hours but can be delayed 1
Common Pitfalls to Avoid
- Do not continue oral urate-lowering therapy concurrently—this must be stopped before pegloticase initiation 1
- Do not ignore rising serum uric acid levels—loss of urate-lowering response (serum uric acid >6 mg/dL) predicts increased infusion reaction risk, with 10 of 11 serious infusion reactions occurring when uric acid exceeded 6 mg/dL 3
- Do not skip pre-medication—antihistamines and corticosteroids are mandatory before each infusion 1
Enhanced Response with Immunomodulation
- Co-administration with methotrexate (15 mg/week starting 4 weeks before pegloticase) significantly improves response rates (79-89% vs 42% with pegloticase monotherapy) and reduces infusion reaction risk 4, 6
- This approach is increasingly used in clinical practice, though not yet reflected in the FDA label 1